1038 related articles for article (PubMed ID: 34755538)
41. A review of potential suggested drugs for coronavirus disease (COVID-19) treatment.
Tarighi P; Eftekhari S; Chizari M; Sabernavaei M; Jafari D; Mirzabeigi P
Eur J Pharmacol; 2021 Mar; 895():173890. PubMed ID: 33482181
[TBL] [Abstract][Full Text] [Related]
42. Identification of antiviral antihistamines for COVID-19 repurposing.
Reznikov LR; Norris MH; Vashisht R; Bluhm AP; Li D; Liao YJ; Brown A; Butte AJ; Ostrov DA
Biochem Biophys Res Commun; 2021 Jan; 538():173-179. PubMed ID: 33309272
[TBL] [Abstract][Full Text] [Related]
43. COVID-19: Potential Repurposing Drugs.
Leowattana W
Infect Disord Drug Targets; 2022; 22(1):e110122191924. PubMed ID: 33645490
[TBL] [Abstract][Full Text] [Related]
44. IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
Hahn F; Wangen C; Häge S; Peter AS; Dobler G; Hurst B; Julander J; Fuchs J; Ruzsics Z; Überla K; Jäck HM; Ptak R; Muehler A; Gröppel M; Vitt D; Peelen E; Kohlhof H; Marschall M
Viruses; 2020 Dec; 12(12):. PubMed ID: 33291455
[TBL] [Abstract][Full Text] [Related]
45. Kite-Shaped Molecules Block SARS-CoV-2 Cell Entry at a Post-Attachment Step.
Chan SW; Shafi T; Ford RC
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835112
[TBL] [Abstract][Full Text] [Related]
46. Repurposing Drugs for COVID-19: An Approach for Treatment in the Pandemic.
Khadka S; Yuchi A; Shrestha DB; Budhathoki P; Al-Subari SMM; Ziad Alhouzani TM; Anwar Butt I
Altern Ther Health Med; 2020 Aug; 26(S2):100-107. PubMed ID: 32827400
[TBL] [Abstract][Full Text] [Related]
47. Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2.
Xiao X; Wang C; Chang D; Wang Y; Dong X; Jiao T; Zhao Z; Ren L; Dela Cruz CS; Sharma L; Lei X; Wang J
Front Immunol; 2020; 11():586572. PubMed ID: 33324406
[TBL] [Abstract][Full Text] [Related]
48. Drugs repurposing for SARS-CoV-2: new insight of COVID-19 druggability.
Debnath SK; Debnath M; Srivastava R; Omri A
Expert Rev Anti Infect Ther; 2022 Sep; 20(9):1187-1204. PubMed ID: 35615888
[TBL] [Abstract][Full Text] [Related]
49. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Yao X; Ye F; Zhang M; Cui C; Huang B; Niu P; Liu X; Zhao L; Dong E; Song C; Zhan S; Lu R; Li H; Tan W; Liu D
Clin Infect Dis; 2020 Jul; 71(15):732-739. PubMed ID: 32150618
[TBL] [Abstract][Full Text] [Related]
50. SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19.
Fiscon G; Conte F; Farina L; Paci P
PLoS Comput Biol; 2021 Feb; 17(2):e1008686. PubMed ID: 33544720
[TBL] [Abstract][Full Text] [Related]
51. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
Nascimento Junior JAC; Santos AM; Quintans-Júnior LJ; Walker CIB; Borges LP; Serafini MR
Expert Opin Ther Pat; 2020 Aug; 30(8):567-579. PubMed ID: 32429703
[TBL] [Abstract][Full Text] [Related]
52. Rifampicin and Letermovir as potential repurposed drug candidate for COVID-19 treatment: insights from an in-silico study.
Pathak Y; Mishra A; Choudhir G; Kumar A; Tripathi V
Pharmacol Rep; 2021 Jun; 73(3):926-938. PubMed ID: 33970450
[TBL] [Abstract][Full Text] [Related]
53. Comparative transcriptome analysis of SARS-CoV, MERS-CoV, and SARS-CoV-2 to identify potential pathways for drug repurposing.
Krishnamoorthy P; Raj AS; Roy S; Kumar NS; Kumar H
Comput Biol Med; 2021 Jan; 128():104123. PubMed ID: 33260034
[TBL] [Abstract][Full Text] [Related]
54. Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review.
Mohamed K; Yazdanpanah N; Saghazadeh A; Rezaei N
Bioorg Chem; 2021 Jan; 106():104490. PubMed ID: 33261845
[TBL] [Abstract][Full Text] [Related]
55. Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors.
Milani M; Donalisio M; Bonotto RM; Schneider E; Arduino I; Boni F; Lembo D; Marcello A; Mastrangelo E
Antiviral Res; 2021 May; 189():105055. PubMed ID: 33713730
[TBL] [Abstract][Full Text] [Related]
56. Perspectives for repurposing drugs for the coronavirus disease 2019.
Cherian SS; Agrawal M; Basu A; Abraham P; Gangakhedkar RR; Bhargava B
Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):160-171. PubMed ID: 32317408
[TBL] [Abstract][Full Text] [Related]
57. Drug Discovery of Small Molecules for the Treatment of COVID-19: A Review on Clinical Studies.
Goel B; Bhardwaj N; Tripathi N; Jain SK
Mini Rev Med Chem; 2021; 21(12):1431-1456. PubMed ID: 33371848
[TBL] [Abstract][Full Text] [Related]
58. Lycorine, a non-nucleoside RNA dependent RNA polymerase inhibitor, as potential treatment for emerging coronavirus infections.
Jin YH; Min JS; Jeon S; Lee J; Kim S; Park T; Park D; Jang MS; Park CM; Song JH; Kim HR; Kwon S
Phytomedicine; 2021 Jun; 86():153440. PubMed ID: 33376043
[TBL] [Abstract][Full Text] [Related]
59. Repurposing Nucleoside Analogs for Human Coronaviruses.
Zandi K; Amblard F; Musall K; Downs-Bowen J; Kleinbard R; Oo A; Cao D; Liang B; Russell OO; McBrayer T; Bassit L; Kim B; Schinazi RF
Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33122172
[TBL] [Abstract][Full Text] [Related]
60. Uncovering Flexible Active Site Conformations of SARS-CoV-2 3CL Proteases through Protease Pharmacophore Clusters and COVID-19 Drug Repurposing.
Pathak N; Chen YT; Hsu YC; Hsu NY; Kuo CJ; Tsai HP; Kang JJ; Huang CH; Chang SY; Chang YH; Liang PH; Yang JM
ACS Nano; 2021 Jan; 15(1):857-872. PubMed ID: 33373194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]